MX2017011879A - Inhibidores de pcsk9 para el tratamiento de trastornos del metabolismo de lipoproteínas". - Google Patents
Inhibidores de pcsk9 para el tratamiento de trastornos del metabolismo de lipoproteínas".Info
- Publication number
- MX2017011879A MX2017011879A MX2017011879A MX2017011879A MX2017011879A MX 2017011879 A MX2017011879 A MX 2017011879A MX 2017011879 A MX2017011879 A MX 2017011879A MX 2017011879 A MX2017011879 A MX 2017011879A MX 2017011879 A MX2017011879 A MX 2017011879A
- Authority
- MX
- Mexico
- Prior art keywords
- pcsk9
- inhibitors
- treatment
- metabolism disorders
- lipoprotein metabolism
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Materials Engineering (AREA)
- Genetics & Genomics (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente divulgación hace referencia a inhibidores de proteína convertasa subtilisina/kexina tipo 9 (PCSK9) para el tratamiento de trastornos del metabolismo de lipoproteínas.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201570158 | 2015-03-20 | ||
DKPA201570623 | 2015-10-02 | ||
DKPA201570839 | 2015-12-21 | ||
PCT/DK2016/050082 WO2016150444A1 (en) | 2015-03-20 | 2016-03-18 | Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017011879A true MX2017011879A (es) | 2018-04-10 |
Family
ID=55696811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017011879A MX2017011879A (es) | 2015-03-20 | 2016-03-18 | Inhibidores de pcsk9 para el tratamiento de trastornos del metabolismo de lipoproteínas". |
Country Status (10)
Country | Link |
---|---|
US (3) | US10688119B2 (es) |
EP (2) | EP3271405A1 (es) |
JP (2) | JP6869894B2 (es) |
KR (1) | KR20170123345A (es) |
CN (1) | CN107531798B (es) |
AU (2) | AU2016235662B2 (es) |
BR (1) | BR112017020091A2 (es) |
CA (1) | CA2979756A1 (es) |
MX (1) | MX2017011879A (es) |
WO (1) | WO2016150444A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3271405A1 (en) | 2015-03-20 | 2018-01-24 | Aarhus Universitet | Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders |
EP3515455B1 (en) | 2016-09-20 | 2021-04-14 | Aarhus Universitet | Compounds for treatment of lipoprotein metabolism disorders |
CN108753821A (zh) * | 2018-06-13 | 2018-11-06 | 黄河科技学院 | 一种基于细胞的pcsk9抑制剂筛选方法 |
WO2020010186A1 (en) * | 2018-07-06 | 2020-01-09 | Derek Klarin | Pcsk9 variants |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3422407A1 (de) * | 1984-06-16 | 1986-03-06 | B. Braun Melsungen Ag, 3508 Melsungen | Verwendung von heparinderivaten zur selektiven extrakorporalen praezipitation von low-density-lipoproteinen aus vollserum oder plasma |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
AU2753292A (en) | 1991-10-04 | 1993-05-03 | Procter & Gamble Company, The | Cholesterol lowering compounds and process for making them |
AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
GB9221657D0 (en) | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant bispecific antibodies |
EP0628078B1 (en) | 1992-12-11 | 1999-12-08 | The Dow Chemical Company | Multivalent single chain antibodies |
US6255296B1 (en) * | 1994-01-11 | 2001-07-03 | Endomatrix, Inc. | Composition and method for treating a patient susceptible to or suffering from a cardiovascular disorder or disease |
JP2001089382A (ja) * | 1999-09-07 | 2001-04-03 | Pharmacia & Upjohn Ab | 早期血管再生及び低分子量ヘパリン投与による不安定冠動脈疾患の治療方法 |
IL155977A0 (en) | 2000-11-30 | 2003-12-23 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
UA80399C2 (en) * | 2001-11-13 | 2007-09-25 | Glaxo Group Ltd | Use of specific dose of fondaparinux sodium for the treatment of acs |
JP4554910B2 (ja) * | 2002-11-01 | 2010-09-29 | 生化学工業株式会社 | 血糖低下剤 |
AU2004216541A1 (en) * | 2003-02-28 | 2004-09-10 | Howard Florey Institute Of Experimental Physiology And Medicine | Therapeutic compositions |
EP2444494B1 (en) * | 2006-10-09 | 2016-09-28 | Roche Innovation Center Copenhagen A/S | Rna antagonist compounds for the modulation of pcsk9 |
CN101679979A (zh) * | 2007-03-24 | 2010-03-24 | 基酶有限公司 | 施用与人载脂蛋白b互补的反义寡核苷酸 |
JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
CN104666318A (zh) | 2007-10-16 | 2015-06-03 | 普罗吉恩制药有限公司 | 新的硫酸化寡糖衍生物 |
JP2011501952A (ja) * | 2007-10-26 | 2011-01-20 | シェーリング コーポレイション | 脂質障害およびコレステロール障害を治療するための抗pcsk9および方法 |
ES2340902B1 (es) * | 2008-07-01 | 2011-05-03 | Laboratorios Farmaceuticos Rovi, S.A. | Composicion farmaceutica con glicosaminoglicanos y su uso en tratamiento de ulceras cronicas. |
TWI445716B (zh) | 2008-09-12 | 2014-07-21 | Rinat Neuroscience Corp | Pcsk9拮抗劑類 |
CN101757019B (zh) * | 2008-11-10 | 2011-06-08 | 鲁南制药集团股份有限公司 | 用于减肥或治疗代谢综合征的药物组合物 |
JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
PT2483266E (pt) * | 2009-10-01 | 2015-06-30 | Cadila Healthcare Ltd | Compostos para o tratamento da dislipidemia e doenças relacionadas |
CN102656153B (zh) | 2009-10-29 | 2015-02-18 | 延世大学校产学协力团 | 新型血管渗漏阻断剂 |
AR079336A1 (es) * | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
SG191219A1 (en) * | 2010-12-22 | 2013-07-31 | Genentech Inc | Anti-pcsk9 antibodies and methods of use |
CN102526739B (zh) * | 2010-12-27 | 2014-12-03 | 鲁南制药集团股份有限公司 | 治疗糖尿病的药物组合物及其应用 |
AR084938A1 (es) | 2011-01-28 | 2013-07-10 | Sanofi Sa | Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes |
MX2013009258A (es) | 2011-02-11 | 2013-10-17 | Novartis Ag | Antagonistas de pcsk9. |
AR087715A1 (es) | 2011-09-16 | 2014-04-09 | Lilly Co Eli | Anticuerpos anti pcsk9 y usos de los mismos |
JP6170940B2 (ja) | 2011-12-20 | 2017-07-26 | アダエラータ、リミテッド パートナーシップAdaerata, Limited Partnership | Pcsk9の阻害剤としての単一ドメイン抗体 |
WO2013148284A1 (en) | 2012-03-29 | 2013-10-03 | Genentech, Inc. | Antibodies that bind to a pcsk9 cleavage site and methods of use |
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
CA2874244A1 (en) | 2012-05-25 | 2013-11-28 | Catabasis Pharmaceuticals, Inc. | Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9) |
US20150190369A1 (en) * | 2012-07-03 | 2015-07-09 | Majambu Mbikay | Quercetin-3-glucoside and uses thereof |
WO2014107739A1 (en) | 2013-01-07 | 2014-07-10 | Eleven Biotherapeutics, Inc. | Antibodies against pcsk9 |
CA2905237A1 (en) * | 2013-03-15 | 2014-09-18 | Adaerata, Limited Partnership | Small molecule modulators of pcsk9 and methods of use thereof |
CA2906508A1 (en) * | 2013-03-15 | 2014-09-25 | Amgen, Inc. | Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 |
US9480703B2 (en) * | 2013-10-29 | 2016-11-01 | Shaker A. Mousa | Method and composition of glycosaminoglycans in sickle cell and vascular disorders |
EP3271405A1 (en) | 2015-03-20 | 2018-01-24 | Aarhus Universitet | Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders |
EP3515455B1 (en) * | 2016-09-20 | 2021-04-14 | Aarhus Universitet | Compounds for treatment of lipoprotein metabolism disorders |
-
2016
- 2016-03-18 EP EP16714751.1A patent/EP3271405A1/en not_active Withdrawn
- 2016-03-18 US US15/558,491 patent/US10688119B2/en not_active Expired - Fee Related
- 2016-03-18 EP EP21175700.0A patent/EP3973958A3/en not_active Withdrawn
- 2016-03-18 WO PCT/DK2016/050082 patent/WO2016150444A1/en active Application Filing
- 2016-03-18 MX MX2017011879A patent/MX2017011879A/es unknown
- 2016-03-18 BR BR112017020091-0A patent/BR112017020091A2/pt not_active IP Right Cessation
- 2016-03-18 KR KR1020177030055A patent/KR20170123345A/ko not_active Application Discontinuation
- 2016-03-18 CN CN201680026131.4A patent/CN107531798B/zh not_active Expired - Fee Related
- 2016-03-18 CA CA2979756A patent/CA2979756A1/en active Pending
- 2016-03-18 JP JP2017549203A patent/JP6869894B2/ja active Active
- 2016-03-18 AU AU2016235662A patent/AU2016235662B2/en not_active Ceased
-
2020
- 2020-05-04 US US16/865,661 patent/US20200330504A1/en not_active Abandoned
- 2020-10-15 AU AU2020256388A patent/AU2020256388A1/en not_active Abandoned
-
2021
- 2021-04-14 JP JP2021068527A patent/JP2021119148A/ja active Pending
- 2021-11-22 US US17/532,414 patent/US20220072032A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2021119148A (ja) | 2021-08-12 |
EP3271405A1 (en) | 2018-01-24 |
JP2018511596A (ja) | 2018-04-26 |
JP6869894B2 (ja) | 2021-05-12 |
AU2016235662A1 (en) | 2017-10-12 |
AU2016235662B2 (en) | 2020-07-30 |
US20180193376A1 (en) | 2018-07-12 |
US10688119B2 (en) | 2020-06-23 |
KR20170123345A (ko) | 2017-11-07 |
EP3973958A3 (en) | 2022-06-22 |
BR112017020091A2 (pt) | 2018-11-06 |
AU2020256388A1 (en) | 2020-11-12 |
CN107531798A (zh) | 2018-01-02 |
EP3973958A2 (en) | 2022-03-30 |
WO2016150444A1 (en) | 2016-09-29 |
US20200330504A1 (en) | 2020-10-22 |
CA2979756A1 (en) | 2016-09-29 |
US20220072032A1 (en) | 2022-03-10 |
CN107531798B (zh) | 2022-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023000251A (es) | Composiciones para usarse en el tratamiento de un trastorno asociado a gen de proproteina convertasa subtilisina kexina (pcsk9). | |
HK1243075A1 (zh) | 使前蛋白轉化酶枯草溶菌素/ kexin 9型(pcsk9)減少的方法 | |
CL2018000914A1 (es) | Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-en-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adicción y carcinoma hepatocelular | |
MX2018005600A (es) | Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello. | |
EP2968266A4 (en) | KEXINE ANTI-PROPERTY CONVERTASE CONVERTASE COMPOUNDS TYPE 9 (ANTI-PCSK9) AND METHODS OF USING THE SAME FOR THE TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASES | |
ZA201409210B (en) | Methods and uses for proprotein convertase subtilisin kexin 9 (pcsk9) inhibitors | |
PH12015502761A1 (en) | Antisense oligomers and conjugates targeting pcsk9 | |
IL266066A (en) | Methods for preventing cardiovascular events by reducing the protein proprotein convertase subtilisin kexin 9 | |
MX2017003624A (es) | Compuestos de piridona sustituida con pirazolilo como inhibidores de serina proteasas. | |
EA201691447A1 (ru) | 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера | |
MY168961A (en) | Antibodies to pcsk9 and uses thereof | |
EA201792503A1 (ru) | Соль (s)-kck s-кетамина, соль (r)-kck s-кетамина и способы получения s-кетамина | |
MY179341A (en) | Method for producing l-amino acids using an alkaliphilic bacteria | |
MX2018008105A (es) | Compuestos inhibidores de metaloenzima. | |
EA201600589A1 (ru) | Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств | |
SG10201907699YA (en) | Substituted pyrazole compounds as serine protease inhibitors | |
MX2017011879A (es) | Inhibidores de pcsk9 para el tratamiento de trastornos del metabolismo de lipoproteínas". | |
PH12019500751A1 (en) | Carbamoyl phenylalaninol compounds and uses thereof | |
MX2019001011A (es) | Compuestos farmaceuticos. | |
MX2023005484A (es) | Analogos de carbamoil fenilalaninol y usos de los mismos. | |
HK1257102A1 (zh) | 苯基哌嗪前蛋白轉化酶枯草桿菌蛋白酶/kexin9型(pcsk9)調節劑及其應用 | |
EP3182971A4 (en) | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9) protein activity | |
EA201792610A1 (ru) | Способ лечения неврологического заболевания | |
IL283374A (en) | Cyclic tetramer compounds as (pcsk9) type 9 subtilisin/kexin convertase protein inhibitors for the treatment of metabolic disorders | |
GEP201706795B (en) | Hexahydrofuropyrroles as pde1 inhibitors |